849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Breast Cancer	Jennifer Zhang	P3	B (59)
Panobinostat Breast Cancer	Dana-Farber Cancer Institute	P2	B (59)
Sorafenib Breast Cancer	Fudan University	P3	B (59)
Tranexamic Acid Breast Cancer	University of Virginia	P4	B (59)
Trastuzumab Emtansine For Breast Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P3	B (59)
Veliparib Breast Cancer	The University of Texas Health Science Center at San Antonio	P3	B (59)
Xzp-3287 Breast Cancer	Xuanzhu Biopharmaceutical Co., Ltd.	P3	B (59)
17b-estradiol Breast Cancer	Mary D Chamberlin	P2	B (58)
2-PROPENOIC ACID, 3-(3,5-DICHLORO-4-((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL)-2,3,4,9-TETRAHYDRO-3-METHYL-1H-PYRIDO(3,4-B)INDOL-1-YL)PHENYL)-, (2E)- Breast Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	B (58)
Bendamustine Breast Cancer	University of Zurich	P2	B (58)
c105 Breast Cancer	University of Washington	P2	B (58)
Carvedilol Breast Cancer	Mayo Clinic	P3	B (58)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine Breast Cancer	University of Washington	P2	B (58)
Dasatinib Breast Cancer	National Cancer Institute (NCI)	P2	B (58)
Datopotamab Deruxtecan Breast Cancer	UNC Lineberger Comprehensive Cancer Center	P3	B (58)
D-Thioctic Acid Breast Cancer	Ain Shams University	P4	B (58)
Durvalumab Breast Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (58)
Enzalutamide Breast Cancer	Memorial Sloan Kettering Cancer Center	P3	B (58)
Eribulin Mesilate Breast Cancer	MedSIR	P3	B (58)
Gadobutrol Breast Cancer	Wake Forest University Health Sciences	P3	B (58)
Gm-Csf Breast Cancer	Washington University School of Medicine	P2	B (58)
Huaier Granule Breast Cancer	Fudan University	P4	B (58)
Hydromorphon Breast Cancer	Ohio State University Comprehensive Cancer Center	P3	B (58)
Imatinib Breast Cancer	Vastra Gotaland Region	P4	B (58)
L-Bupivacaine Breast Cancer	University of Rijeka	P4	B (58)
Lobaplatin Breast Cancer	Shandong Cancer Hospital and Institute	P4	B (58)
Mitoxantrone Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	B (58)
Moxifloxacin Breast Cancer	Sun Yat-sen University	P3	B (58)
NORVIR Breast Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	B (58)
Olanzapine Breast Cancer	Chinese University of Hong Kong	P3	B (58)
Omeprazole Breast Cancer	Genentech, Inc.	P3	B (58)
Palonosetron Breast Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P4	B (58)
Pembrolizumab Breast Cancer	West German Study Group	P3	B (58)
Pentoxifylline Breast Cancer	Tanta University	P2/3	B (58)
Regorafenib Breast Cancer	OHSU Knight Cancer Institute	P2	B (58)
Retifanlimab Breast Cancer	M.D. Anderson Cancer Center	P3	B (58)
Ruxolitinib Breast Cancer	Baylor Research Institute	P2	B (58)
Sacituzumab Tirumotecan Breast Cancer	Shanghai Jiao Tong University School of Medicine	P3	B (58)
Sevoflurane Breast Cancer	Moscow Clinical Scientific Center	P4	B (58)
Sirolimus Breast Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P3	B (58)
Sry-Box Transcription Factor 2 Breast Cancer	University of Washington	P2	B (58)
TIL Breast Cancer	Essen Biotech	P2	B (58)
Tirzepatide Breast Cancer	Universitaire Ziekenhuizen KU Leuven	P4	B (58)
tqb2101 for Breast Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P3	B (58)
tqb2102 Breast Cancer	Henan Cancer Hospital	P3	B (58)
Tretinoin Breast Cancer	Peking University People's Hospital	P2	B (58)
Tucatinib Breast Cancer	MedSIR	P3	B (58)
Utidelone Breast Cancer	Beijing Biostar Pharmaceuticals Co., Ltd.	P3	B (58)
Yb-1 Breast Cancer	University of Washington	P2	B (58)
Anhydrous Enol-Oxaloacetate Breast Cancer	Jonsson Comprehensive Cancer Center	P2	B (57)

Showing 151 to 200 of 849 assets

PreviousPage 4 of 17Next